An Open-Label Study of the Safety of Interferon Gamma-1b in Patients With IPF
Status:
Terminated
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
Open-label therapy will be administered to up to 220 patients, following completion of either
InterMune Protocol GIPF-002 Part B or Protocol GIPF-004, to assess the long-term safety of
subcutaneous Interferon gamma-1b. The study duration will be 5 years.